GLP-1 Drugs and Psoriasis Healthcare Use

On 21 August 2026, the Journal of the European Academy of Dermatology and Venereology (JEADV) published a new letter by Marc Hill, Alison Treichel and Kevin Cooper, of Case Western Reserve University and University Hospitals Cleveland Medical Center, asking a narrower question than most coverage of tirzepatide and semaglutide in psoriasis usually asks. The title identifies healthcare resource usage as its focus: how much medical care psoriasis patients on a GLP-1 or dual GIP/GLP-1 receptor agonist use^[1]. That is a different endpoint from disease control, and the difference is the whole point of this article.

What we can confirm about the new letter

PubMed lists the piece as a Letter, a short-communication format rather than a full original-research article with its own structured abstract. The journal's own indexing confirms the scope: the listed keywords are healthcare resource utilization, psoriasis, obesity, semaglutide, tirzepatide and liraglutide^[1]. As of this writing, the full text sits behind the journal's subscription wall and PubMed has not yet published an abstract for it. We are not going to guess at sample size, effect direction or magnitude we have not verified. What follows instead is the surrounding evidence we could confirm in full, so the new letter has real context rather than a vacuum around it.

What healthcare resource usage means, and what it does not mean

Healthcare resource usage, HCRU for short, is a health-economics term for how often patients show up in the medical system: hospital admissions, emergency-department visits, specialist appointments, prescriptions filled, and the costs attached to all of it. It is a proxy for the overall burden a condition places on a patient and a health system. It is not a measurement of skin severity. A drop in HCRU could reflect fewer flare-ups, but it could just as easily reflect fewer heart attacks, fewer hospital stays for an unrelated complication, or simply patients who are engaging less with the healthcare system for reasons that have nothing to do with their psoriasis.

That distinction matters because no GLP-1 or dual GIP/GLP-1 receptor agonist is approved by the FDA, EMA or MHRA to treat psoriasis. Tirzepatide and semaglutide are approved for type-2 diabetes, chronic weight management, and a small set of related indications, detailed on our tirzepatide regulation page and semaglutide regulation page. A study measuring reduced healthcare visits in psoriasis patients who happen to be taking one of these drugs for diabetes or obesity is not the same evidence as a trial proving the drug treats psoriasis.

What the rest of the 2026 real-world data already shows

Two other 2026 publications provide context from US TriNetX electronic-health-record data, with publicly available results. Olbrich and colleagues matched 3,048 psoriasis patients on a GLP-1 receptor agonist against 3,048 psoriasis patients on other antidiabetic or antiobesity drugs and followed them for two years. GLP-1RA treatment was associated with significantly lower all-cause mortality (hazard ratio 0.219), fewer major adverse cardiac events (hazard ratio 0.561), and lower rates of alcohol and substance-use diagnoses, all statistically significant, without more frequent adverse drug events in the GLP-1RA group^[2].

A second letter in the same journal, from Ma and colleagues, matched 41,873 psoriasis patients on a GLP-1 receptor agonist against an equal number of non-users out of a pool of 646,438 psoriasis patients. Over five years, GLP-1RA use tracked with lower odds of cerebrovascular disease, heart failure, atherosclerosis and procedures like percutaneous coronary intervention^[3]. Fewer strokes, heart-failure admissions and cardiac procedures are exactly the kind of events that drive hospitalizations and emergency-department visits, the raw material of a healthcare-resource-usage count. If the new Hill, Treichel and Cooper letter finds a similar direction, that would fit the pattern these two studies already show. We cannot confirm that from what is public today, only that the pattern already exists in adjacent, fully readable data.

What the skin-specific evidence says, separately

The accessible material does not establish whether the new Hill letter measured psoriasis skin severity. Skin-specific evidence should be assessed separately. The most current synthesis of the studies that do, the National Psoriasis Foundation's 2026 primer for dermatologists, found that reported improvements in Psoriasis Area and Severity Index (PASI) scores come mostly from small studies of 7 to 48 patients, lasting six months or less, and usually without a control group^[4]. The primer describes real biological plausibility, including reductions in inflammatory markers like C-reactive protein and interleukin-6, but its own authors are explicit that definitive conclusions await larger randomized trials. A big real-world dataset showing fewer hospital visits is a genuinely different kind of evidence than a small, uncontrolled study showing less redness and scale, and readers should not collapse the two.

Practical context

If you have psoriasis and are already on tirzepatide or semaglutide for diabetes or weight management, or you are considering one of these drugs for those approved uses, this research is a reason for an informed conversation with your prescriber and your dermatologist, not a reason to start or stop a medicine to treat your skin. The literature on healthcare utilization is encouraging for the overall health of psoriasis patients who have diabetes or obesity alongside their skin disease. It is not yet evidence that these drugs belong in a psoriasis treatment plan on their own.